Unique Wealth LLC Invests $218,000 in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Unique Wealth LLC acquired a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 519 shares of the company's stock, valued at approximately $218,000.

Several other institutional investors also recently bought and sold shares of the company. Financial Advocates Investment Management raised its holdings in shares of IDEXX Laboratories by 28.7% in the fourth quarter. Financial Advocates Investment Management now owns 1,008 shares of the company's stock valued at $417,000 after acquiring an additional 225 shares in the last quarter. Silver Oak Securities Incorporated increased its position in IDEXX Laboratories by 84.0% during the 4th quarter. Silver Oak Securities Incorporated now owns 631 shares of the company's stock valued at $260,000 after purchasing an additional 288 shares during the period. 1900 Wealth Management LLC increased its position in IDEXX Laboratories by 6.9% during the 4th quarter. 1900 Wealth Management LLC now owns 775 shares of the company's stock valued at $320,000 after purchasing an additional 50 shares during the period. Sumitomo Mitsui Trust Group Inc. raised its holdings in shares of IDEXX Laboratories by 0.5% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 198,450 shares of the company's stock valued at $82,047,000 after purchasing an additional 916 shares in the last quarter. Finally, Lecap Asset Management Ltd. lifted its position in shares of IDEXX Laboratories by 587.7% in the 4th quarter. Lecap Asset Management Ltd. now owns 5,701 shares of the company's stock worth $2,357,000 after purchasing an additional 4,872 shares during the period. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, Director M Anne Szostak sold 1,260 shares of the company's stock in a transaction that occurred on Wednesday, May 21st. The shares were sold at an average price of $512.34, for a total transaction of $645,548.40. Following the transaction, the director now owns 1,801 shares in the company, valued at approximately $922,724.34. This represents a 41.16% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.98% of the stock is currently owned by corporate insiders.

IDEXX Laboratories Stock Up 0.5%

NASDAQ:IDXX traded up $2.70 during midday trading on Friday, reaching $524.91. 265,338 shares of the stock traded hands, compared to its average volume of 651,744. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $530.73. The business has a 50-day moving average of $460.16 and a two-hundred day moving average of $440.88. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. The stock has a market capitalization of $42.21 billion, a PE ratio of 49.19, a price-to-earnings-growth ratio of 3.41 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported $2.96 EPS for the quarter, beating analysts' consensus estimates of $2.93 by $0.03. IDEXX Laboratories had a net margin of 22.78% and a return on equity of 55.82%. The company had revenue of $998.43 million during the quarter, compared to analysts' expectations of $998.25 million. During the same quarter in the prior year, the company posted $2.71 earnings per share. IDEXX Laboratories's revenue for the quarter was up 3.6% compared to the same quarter last year. On average, equities analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently issued reports on IDXX. Stifel Nicolaus lifted their price objective on shares of IDEXX Laboratories from $460.00 to $510.00 and gave the company a "hold" rating in a report on Monday, May 19th. Wall Street Zen downgraded IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Friday, May 30th. Piper Sandler boosted their price target on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a research report on Monday, February 10th. Finally, Morgan Stanley raised their price objective on IDEXX Laboratories from $548.00 to $558.00 and gave the company an "overweight" rating in a research report on Monday, May 5th. Four analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $536.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.